Trabectedin for metastatic soft tissue sarcoma: a retrospective single center analysis. - Wikidata - wikimedia - TriplyDB

Trabectedin for metastatic soft tissue sarcoma: a retrospective single center analysis.

Trabectedin for metastatic soft tissue sarcoma: a retrospective single center analysis.

http://www.wikidata.org/entity/Q34356540

about

Trabectedin for inoperable or recurrent soft tissue sarcoma in adult patients: a retrospective cohort study.Therapy-related acute myeloid leukemia following treatment with trabectedin for Ewing's sarcoma.

P2860

Q35898258-69E71785-9502-473D-A749-69A7C45A1A26 Q45988744-7D00A9A5-2E2D-481E-8CCF-ED15C57D09C8

P2860

Trabectedin for metastatic soft tissue sarcoma: a retrospective single center analysis.

http://www.wikidata.org/entity/Q34356540

description

2010 nî lūn-bûn

@nan

2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Trabectedin for metastatic soft tissue sarcoma: a retrospective single center analysis.

@ast

Trabectedin for metastatic soft tissue sarcoma: a retrospective single center analysis.

@en

Trabectedin for metastatic soft tissue sarcoma: a retrospective single center analysis.

@nl

type

label

Trabectedin for metastatic soft tissue sarcoma: a retrospective single center analysis.

@ast

Trabectedin for metastatic soft tissue sarcoma: a retrospective single center analysis.

@en

Trabectedin for metastatic soft tissue sarcoma: a retrospective single center analysis.

@nl

prefLabel

Trabectedin for metastatic soft tissue sarcoma: a retrospective single center analysis.

@ast

Trabectedin for metastatic soft tissue sarcoma: a retrospective single center analysis.

@en

Trabectedin for metastatic soft tissue sarcoma: a retrospective single center analysis.

@nl

P1433

Q34356540-D22D717F-C5BC-4DCF-9CF3-1BC7A142F6D9

P1476

Q34356540-4542DD7D-0007-4968-8052-17FB90774689

P2093

Q34356540-0D4950F0-600B-4846-9422-7450B5938AAE

Q34356540-13363BB8-8911-4844-AA71-759745341E68

Q34356540-36E2127E-733E-4649-B547-372C893AF6AF

Q34356540-B398C769-1317-4A7D-AF89-ABE9B3E9914F

Q34356540-E3F86B9D-1BDB-4C1A-B74E-3923E300037D

P2860

Q34356540-171C5CF9-5D87-4482-82C4-33DAA22BC64D

Q34356540-18FFE541-0122-4EEB-A79D-D7ED445FC84A

Q34356540-278484E8-709E-4E48-8AD1-D4ACC9604B4C

Q34356540-32DD5B97-0E61-45AB-901A-F1816D5ED97B

Q34356540-36A3C47A-6C35-42BB-A40B-1B4069612B8C

Q34356540-3F59A8A8-AF54-4C98-9A43-871D1A1AA8A5

Q34356540-4426381F-1C47-44B5-9CBB-4F07A8ECB383

Q34356540-446DAA63-BE32-4126-B2FA-DBE837883744

Q34356540-4A57636E-F096-4E7F-8A77-1E3DCBE8B968

Q34356540-525C0470-E490-4CA8-B832-ADD0ABB821E9

P304

Q34356540-41090E3B-0977-4643-ADA1-B950132E6F25

P31

Q34356540-F9880326-80AA-45A5-AF1F-A7C95445953B

P356

Q34356540-F9943CFB-6B19-4F24-BF06-BC49D9EDDF89

P433

Q34356540-197E57E0-B5FB-4F2A-BBE0-2E707CF3FD35

P478

Q34356540-73BE7FBF-D463-43BE-9BA5-637C092B154E

P50

Q34356540-D7C35610-7F82-4105-9B35-2D93632DF5BD

P577

Q34356540-7886BCFC-7348-4038-BAF0-188EA308898A

P5875

Q34356540-DF30C4D6-CCD3-4CBE-9BF2-8C3E9AF910CA

P698

Q34356540-B86992F8-C234-46FC-B50A-7708997DC30B

P932

Q34356540-D47FA527-9759-4645-9C35-39C173F4AD84

P356

P1433

P1476

Trabectedin for metastatic soft tissue sarcoma: a retrospective single center analysis

@en

P2093

Eva Keller

http://www.w3.org/2001/XMLSchema#string

Gerlinde Egerer

http://www.w3.org/2001/XMLSchema#string

Patrick Wuchter

http://www.w3.org/2001/XMLSchema#string

Sascha Dietrich

http://www.w3.org/2001/XMLSchema#string

Thomas Schmitt

http://www.w3.org/2001/XMLSchema#string

P2860

Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma

Cancer statistics, 2008

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care.

Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma.

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients.

Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial.

Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].

Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.

Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors.

P304

2647-2658

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3390/MD8102647

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-10-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49644072

http://www.w3.org/2001/XMLSchema#string

P698

21116412

http://www.w3.org/2001/XMLSchema#string

P932

2992998

http://www.w3.org/2001/XMLSchema#string